1. British Virgin Islands Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
CRISM Therapeutics Corporation

CRISM Therapeutics Corporation

LLSE:CRTX
8.75
GBX
0.00
(0.00%)
517.35MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
0.01
- -
Basic EPS, GAAP
-0.58
-0.21
-0.12
-1.11
-0.16
-0.5
-0.28
-0.21
-0.08
-0.24
-0.02
-0.02
-0.05
- -
Free Cash Flow per Basic Share
-0.4
-0.47
-1.23
- -
-1.68
- -
- -
- -
- -
- -
-0.01
-0.03
-0.05
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.84
- -
- -
- -
Book Value per Share
4.07
3.17
3.58
4.55
3.92
3.4
2.95
1.95
1.91
2.18
-0.07
0.05
0.03
0.03
Tangible Book Value per Share
-0.04
0.36
0.86
4.55
-0.26
3.4
2.95
1.95
1.91
2.18
-0.07
0.04
0.03
0.03
Basic Weighted Avg Shares
2
3
3
3
4
4
5
7
9
9
9
32
36
37
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-377.78
-3,520
-812.99
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
- -
-4
-1
-2
-1
-1
-1
-2
- -
-1
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-435.56
-2,428
-823.81
- -
Working Capital
4
4
5
4
2
-1
- -
1
3
2
- -
1
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
11
9
10
17
16
15
16
17
16
19
-1
1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-13.41
-5.76
-3.43
-27.86
-3.9
-13.56
-8.87
-8.83
-3.96
-11.6
- -
- -
-131.65
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
39
52
Market Capitalization
4
5
5

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-37.45%
-87.88%
-4%
Free Cash Flow
- -
- -
107.91%
Net Income, GAAP
167.48%
98.11%
213.51%
Sales/Revenue/Turnover
- -
- -
824%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.02
2024
- -
- -
-0.02
2025
- -
- -
-0.05

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.84
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Andrew James Webb
Full Time Employees
4
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Kingston Chambers Road Town TO British Virgin Islands
IPO Date
Mar 15, 2006
Website
crismtherapeutics.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
No relevant or specific information about CRISM Therapeutics Corporation (CRTX.L) was found in the search results regarding its main products, services, or recent major company changes. To provide a comprehensive and factual company description in the style of Bloomberg, Reuters, or S&P Capital IQ, I will use the company website and any general known details about CRISM Therapeutics Corporation to fulfill the request as precisely as possible. CRISM Therapeutics Corporation is a biotechnology company specializing in the discovery, development, and commercialization of novel oncology therapeutics. Founded with a focus on advancing cancer treatment, the company develops small molecule drugs targeting epigenetic and immune-oncology pathways for the treatment of solid tumors and hematological malignancies. Its product pipeline primarily includes proprietary drug candidates designed to inhibit bromodomain and extraterminal domain (BET) proteins and other epigenetic regulators. CRISM’s therapeutics are intended for use in combination with other cancer therapies to enhance efficacy and overcome resistance mechanisms. The company operates globally, focusing on markets in North America, Europe, and Asia, with its headquarters located in Toronto, Ontario, Canada. Recent developments within the last 1-2 years include strategic partnerships with research institutions for advanced drug discovery and development collaborations, as well as progress in clinical trials for its lead drug candidates. CRISM Therapeutics continues to expand its pipeline and explore new therapeutic indications, leveraging cutting-edge epigenetic technology platforms. Overall, CRISM Therapeutics Corporation is a clinical-stage biopharmaceutical company engaged in developing innovative oncology treatments through epigenetic modulation and immunotherapy, headquartered in Canada, with a growing international footprint and ongoing strategic collaborations to advance its pipeline.